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Objectives: To describe mortality trend for CF between 1970 and 2011 in Italy; to
verify the existence of a gender gap; to analyze the full morbidity process leading
to deaths.
Methods: Mortality data were extracted from the database of underlying cause of
death (1970–2011) and multiple causes of death (2003–2010) of the Italian National
Institute of Statistics. Age-speciﬁc mortality rates for CF and age-standardized
mortality ratio (SMR) were calculated to compare mortality between genders. In
order to verify the association between CF and other conditions, we determined
whether the distribution of the potential CF-associated causes of deaths differed
from that of the non-CF population by calculating the Proportionate Mortality Ratio
(PMR).
Results: During the study period, 1947 death certiﬁcates reported CF as the
underlying cause of death. Mortality rates for CF substantially decreased in children
and by the end of the 1990s also in adolescents and young adults. A remarkable
excess in mortality was observed in young CF females (1−29 years) [SMR: 1.30
(95%CI 1.20–1.40)]. Pneumonia (PMR: 4.8), chronic lower respiratory diseases
(PMR: 5.1), sepsis (PMR: 3.4), diabetes mellitus (PMR: 6.7) and renal failure
(PMR: 2.8) were more frequently reported as causes of death in people who died
for CF than in those who did not die for CF.
Conclusion: The mortality trend for CF in Italy reﬂects the effect of the signiﬁcant
advances in treatment over the period. Our results support persistence of a female-
gender disadvantage in mortality for CF. Other diseases not involving the respiratory
tract were found to have contributed to the morbidity process leading to death.
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Objectives: To examine speciﬁc causes of mortality in CF patients in the era of
lung transplantation.
Methods: Deaths in CF patients were identiﬁed using the French national death
registry, which collect data on all death certiﬁcates in France. Individual patients
were identiﬁed using the French Cystic Fibrosis Registry and individual ﬁles were
requested from the CF centers accross France. Mortality causes were adjudicated
by an independent adjudication committee composed of respiratory physicians,
pediatricians and transplant specialists.
Results: Between 2007 and 2010, death certiﬁcates identiﬁed 285 deaths in
CF patients of which 91% (139 women, 120 men) were followed in CF centers
according to the French CF Registry. Median age of death was 26 yrs and the peak
of death occurred between 25 and 30 yrs. Based on CF Registry data, approximately
half the patients died without lung transplantation, although only few patients died
on transplant waiting list. Only 15% of patients died before the age of 20 yrs; a
gender gap was present in infant and adolescents in whom women died twice as
much as men, but not in adults. Speciﬁc causes of death before and after lung
tranplantation are currently being analyzed.
Conclusion: Approximately half of the patients with cystic ﬁbrosis in France
between 2007–2010 died without receiving lung transplantation. Identiﬁcation of
causes leading to the absence of transplantation in these patients may lead to
improvement of survival in CF patients.
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Objectives: To analyze the mutations spectrum among adult CF’s and their outcome.
Methods: All adults at or above 18 years of age at the end of 2013 y, have been
inspected for their mutations, ages at diagnosis, condition and outcome.
Results: Adult CF patients (n = 44, males 25, females 19) consisted 27.07% of
all diagnosed CF patients (n = 119). No signiﬁcant gender and age differences-
37.88% (25/66) males and 35.85% (19/53) females have been detected; median
age was found to be 22.5 y (range 18−34 y) for males and 26.0 y (range 19−58 y)
for females. Two thirds of the patients (30/44) were diagnosed during their very
early childhood and only 4 during adulthood. F508 homozygous were about one
fourth (12/44, 27.27%), another one fourth (12/44, 27.27%) were non F508 and
the rest (21/44, 47.73%) was compound heterozygous for F508. Unknown CF
mutations were 10 (11.36%) − in 7 cases accompanying F508 and in 3 − other
mutation. In total CF alleles consisted: 45 (51.14%) F508, 6 N1303K (6.81%),
4 2184insA (4.54%), 3 R347P (3.40%), 3 1070Q (3.40%), four mutations (G85E,
Q220X, 3849+10KB C-T and 621+1G-T) were found double and the rest (306del
TAGA, G542X, R75Q, N119T, G1244V+S912L, G1069R+L88X, 1898+3G-A,
2183/2184A-G and 4374+G-A) once. The death incidence was 11.36% − mean age
27.5 y and 24.0 y for males/females. Homozygous for F508 was just one. In another
two, F508 was accompanied with R1070Q and 3849+10KB C-T respectively,
another two were not F508 − R349P/R349P and 2184 ins/unknown.
Conclusion: In a situation without available newborn screening program and some
therapeutic and care restrictions the data display optimistic opportunities for a better
life with CF disease.
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Background: Most cystic ﬁbrosis (CF) patients receive medical care in the
specialized multidisciplinary children and adult CF centres worldwide.
Objective: To analyze the patients clinical data of the ﬁrst Adult CF centre in
Lithuania.
Methods: Data analysis from CF registry database (CFdbase v.2.33, St. Luc
University Hospital, Brussels) from January 2009 to December 2013 was done.
Results: Twenty-one CF adult patients were at the end of 2013 (two women died
in 2009 and 2012, one man in 2013). CF diagnosis was conﬁrmed genetically
in 52% of patients (91% of them had DF508). The youngest patient was 18, the
oldest one 32 years. The median age of CF patients was 22.4 (2009), 21.7 (2010),
22.7 (2011), 22.6 (2012) and 23.1 years (2013). The mean BMI was 18.2, 18.5,
18.5, 19.4, 19.8 kg/m2, lung function as mean FEV1 was 50.5%, 63.9%, 59.3%,
75.1%, 57.9% of predicted, respectively. The most prevalent respiratory pathogen
was methicillin-sensitive Staphylococcus aureus − 50.0, 38.9, 26.1, 33.3 and 21.4%;
there were no methicillin-resistant S. aureus. The rate of Pseudomonas spp. was
14.3%, 22.2%, 26.1%, 12.5%, 14.3%, Burkholderia cepacia complex 14.3%, 11.1%,
13.0%, 12.5%, 7.1%, accordingly. The ﬁrst cases of Stenotrophomonas maltophilia
were identiﬁed from 2011. The rate of CF exacerbations requiring hospitalization
was 0.8, 0.9, 0.9, 1.2, 0.9 per person per year, accordingly. Our Centre has successful
experience with pregnant CF woman − she gave birth to a healthy baby without
signiﬁcant complications.
Conclusion: Specialized CF Centre is able to provide a comprehensive medical
care for CF patients and Centre care model is advisable in Lithuania as well.
